Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CVRx ( (CVRX) ).
On April 13, 2026, CVRx reported preliminary, unaudited first-quarter 2026 results showing expected revenue of $14.7 million to $14.8 million, up about 20% from a year earlier, with gross margin improving to roughly 87% and operating expenses rising to about $25 million. As of March 31, 2026, the company had 257 U.S. active implanting centers, 56 domestic sales territories and cash and cash equivalents of approximately $72.3 million, underscoring continued commercial expansion of its Barostim heart failure device.
The company highlighted reimbursement tailwinds after Category I CPT codes for Barostim took effect on January 1, 2026, driving 30-day Medicare Advantage prior authorization approval rates managed in-house from 31% in 2024 to 50% in the first two months of 2026. CVRx also activated the first site in its BENEFIT-HF clinical trial on March 31, 2026, a pivotal study that, if successful, could roughly triple Barostim’s indicated patient population by extending its use to a broader segment of heart failure patients, potentially strengthening the firm’s competitive position and long-term growth prospects.
The most recent analyst rating on (CVRX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on CVRx stock, see the CVRX Stock Forecast page.
Spark’s Take on CVRX Stock
According to Spark, TipRanks’ AI Analyst, CVRX is a Neutral.
The score is held down primarily by weak financial performance (large losses, persistent cash burn, and rising leverage), partially offset by constructive technical momentum and an earnings-call outlook that includes strong gross margins and reimbursement/clinical catalysts despite continued high spending and expected cash burn.
To see Spark’s full report on CVRX stock, click here.
More about CVRx
CVRx, Inc. is a commercial-stage medical device company that develops, manufactures and commercializes neuromodulation solutions for patients with cardiovascular diseases. Its flagship product, Barostim, is an FDA-approved implantable device that delivers electrical pulses to carotid baroreceptors to alleviate heart failure symptoms and is also approved in Europe for heart failure and resistant hypertension.
Barostim is the first neuromodulation technology cleared by the FDA to improve symptoms in heart failure patients and has received Breakthrough Device designation. The therapy is certified under the EU Medical Device Regulation and holds CE Mark approval, giving CVRx a market presence in both the U.S. and European Economic Area for advanced heart failure management.
Average Trading Volume: 359,543
Technical Sentiment Signal: Sell
Current Market Cap: $188.3M
For an in-depth examination of CVRX stock, go to TipRanks’ Overview page.